Cancer risk in long-term users of valproate: a population-based case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cancer risk in long-term users of valproate: a population-based case-control study. / Hallas, Jesper; Friis, Søren; Bjerrum, Lars; Støvring, Henrik; Narverud, Sverre Flatabø; Heyerdahl, Thomas; Grønbaek, Kirsten; Andersen, Morten.

In: Cancer Epidemiology, Biomarkers & Prevention, Vol. 18, No. 6, 2009, p. 1714-9.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hallas, J, Friis, S, Bjerrum, L, Støvring, H, Narverud, SF, Heyerdahl, T, Grønbaek, K & Andersen, M 2009, 'Cancer risk in long-term users of valproate: a population-based case-control study', Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 6, pp. 1714-9. https://doi.org/10.1158/1055-9965.EPI-08-0646

APA

Hallas, J., Friis, S., Bjerrum, L., Støvring, H., Narverud, S. F., Heyerdahl, T., ... Andersen, M. (2009). Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiology, Biomarkers & Prevention, 18(6), 1714-9. https://doi.org/10.1158/1055-9965.EPI-08-0646

Vancouver

Hallas J, Friis S, Bjerrum L, Støvring H, Narverud SF, Heyerdahl T et al. Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiology, Biomarkers & Prevention. 2009;18(6):1714-9. https://doi.org/10.1158/1055-9965.EPI-08-0646

Author

Hallas, Jesper ; Friis, Søren ; Bjerrum, Lars ; Støvring, Henrik ; Narverud, Sverre Flatabø ; Heyerdahl, Thomas ; Grønbaek, Kirsten ; Andersen, Morten. / Cancer risk in long-term users of valproate: a population-based case-control study. In: Cancer Epidemiology, Biomarkers & Prevention. 2009 ; Vol. 18, No. 6. pp. 1714-9.

Bibtex

@article{2f0b40206a3d11df928f000ea68e967b,
title = "Cancer risk in long-term users of valproate: a population-based case-control study",
abstract = "BACKGROUND: Inhibitors of histone deacetylases (HDAC) have shown promise as targeted cancer therapy. Valproate, an older anticonvulsant, has been shown to possess HDAC inhibitory activity. We undertook this case-control study to clarify whether long-term users of valproate had a reduced cancer incidence. If so, it would support HDAC inhibition as a pharmacologic principle in chemoprevention. METHODS: We identified 149,417 incident cancer cases in Denmark during the study period 2000 through 2005, and 597,668 age- and gender-matched controls. Data on history of cancer, past hospital admission diagnoses, and prescription history were obtained from the Danish Cancer Registry, the Danish National Patient Registry, and the Danish Prescription Registry. Primary exposure to valproate was defined as a cumulative dose of minimum 1,500 g within the past 5 years. Confounders were controlled by conditional logistic regression. RESULTS: Among the cases and controls, 81 (0.05{\%}) and 260 (0.04{\%}), respectively, were long-term users of valproate. For cancer overall, the crude and adjusted odds ratios were 1.25 [95{\%} confidence interval (95{\%} CI), 0.97-1.60] and 1.21 (95{\%} CI, 0.95-1.56), respectively. Subgroup analyses revealed no dose or duration effect for overall cancer incidence, and no specific cancer site was found to be inversely associated with long-term use of valproate. For lung cancer, we found a positive but imprecise association (adjusted odds ratio, 2.32; 95{\%} CI, 1.12-4.79). CONCLUSION: Long-term valproate use is not associated with a reduced cancer risk. Our study does not support HDAC inhibition as a pharmacologic principle for general chemoprevention.",
author = "Jesper Hallas and S{\o}ren Friis and Lars Bjerrum and Henrik St{\o}vring and Narverud, {Sverre Flatab{\o}} and Thomas Heyerdahl and Kirsten Gr{\o}nbaek and Morten Andersen",
note = "Keywords: Adult; Age Distribution; Aged; Aged, 80 and over; Anticonvulsants; Case-Control Studies; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Incidence; Male; Middle Aged; Neoplasms; Odds Ratio; Risk Factors; Time; Valproic Acid",
year = "2009",
doi = "10.1158/1055-9965.EPI-08-0646",
language = "English",
volume = "18",
pages = "1714--9",
journal = "Cancer Epidemiology, Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research (A A C R)",
number = "6",

}

RIS

TY - JOUR

T1 - Cancer risk in long-term users of valproate: a population-based case-control study

AU - Hallas, Jesper

AU - Friis, Søren

AU - Bjerrum, Lars

AU - Støvring, Henrik

AU - Narverud, Sverre Flatabø

AU - Heyerdahl, Thomas

AU - Grønbaek, Kirsten

AU - Andersen, Morten

N1 - Keywords: Adult; Age Distribution; Aged; Aged, 80 and over; Anticonvulsants; Case-Control Studies; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Incidence; Male; Middle Aged; Neoplasms; Odds Ratio; Risk Factors; Time; Valproic Acid

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Inhibitors of histone deacetylases (HDAC) have shown promise as targeted cancer therapy. Valproate, an older anticonvulsant, has been shown to possess HDAC inhibitory activity. We undertook this case-control study to clarify whether long-term users of valproate had a reduced cancer incidence. If so, it would support HDAC inhibition as a pharmacologic principle in chemoprevention. METHODS: We identified 149,417 incident cancer cases in Denmark during the study period 2000 through 2005, and 597,668 age- and gender-matched controls. Data on history of cancer, past hospital admission diagnoses, and prescription history were obtained from the Danish Cancer Registry, the Danish National Patient Registry, and the Danish Prescription Registry. Primary exposure to valproate was defined as a cumulative dose of minimum 1,500 g within the past 5 years. Confounders were controlled by conditional logistic regression. RESULTS: Among the cases and controls, 81 (0.05%) and 260 (0.04%), respectively, were long-term users of valproate. For cancer overall, the crude and adjusted odds ratios were 1.25 [95% confidence interval (95% CI), 0.97-1.60] and 1.21 (95% CI, 0.95-1.56), respectively. Subgroup analyses revealed no dose or duration effect for overall cancer incidence, and no specific cancer site was found to be inversely associated with long-term use of valproate. For lung cancer, we found a positive but imprecise association (adjusted odds ratio, 2.32; 95% CI, 1.12-4.79). CONCLUSION: Long-term valproate use is not associated with a reduced cancer risk. Our study does not support HDAC inhibition as a pharmacologic principle for general chemoprevention.

AB - BACKGROUND: Inhibitors of histone deacetylases (HDAC) have shown promise as targeted cancer therapy. Valproate, an older anticonvulsant, has been shown to possess HDAC inhibitory activity. We undertook this case-control study to clarify whether long-term users of valproate had a reduced cancer incidence. If so, it would support HDAC inhibition as a pharmacologic principle in chemoprevention. METHODS: We identified 149,417 incident cancer cases in Denmark during the study period 2000 through 2005, and 597,668 age- and gender-matched controls. Data on history of cancer, past hospital admission diagnoses, and prescription history were obtained from the Danish Cancer Registry, the Danish National Patient Registry, and the Danish Prescription Registry. Primary exposure to valproate was defined as a cumulative dose of minimum 1,500 g within the past 5 years. Confounders were controlled by conditional logistic regression. RESULTS: Among the cases and controls, 81 (0.05%) and 260 (0.04%), respectively, were long-term users of valproate. For cancer overall, the crude and adjusted odds ratios were 1.25 [95% confidence interval (95% CI), 0.97-1.60] and 1.21 (95% CI, 0.95-1.56), respectively. Subgroup analyses revealed no dose or duration effect for overall cancer incidence, and no specific cancer site was found to be inversely associated with long-term use of valproate. For lung cancer, we found a positive but imprecise association (adjusted odds ratio, 2.32; 95% CI, 1.12-4.79). CONCLUSION: Long-term valproate use is not associated with a reduced cancer risk. Our study does not support HDAC inhibition as a pharmacologic principle for general chemoprevention.

U2 - 10.1158/1055-9965.EPI-08-0646

DO - 10.1158/1055-9965.EPI-08-0646

M3 - Journal article

C2 - 19505904

VL - 18

SP - 1714

EP - 1719

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

SN - 1055-9965

IS - 6

ER -

ID: 20009674